Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

InteRNA Technologies Receives Notice of Allowance for miRNA Sequences of its Lead Pre-Clinical Product

Published: Monday, October 15, 2012
Last Updated: Monday, October 15, 2012
Bookmark and Share
Patent covers the precursor and mature sequences of miRNA-3157, the Company's lead product in its B-Raf/melanoma program.

InteRNA Technologies B.V. announces that the United States Patent and Trademark Office (USPTO) has issued the Company a notice of allowance on a patent application covering miRNA sequences, identified through deep sequencing of several different mouse, monkey and human samples, including different tumor samples. The allowable product claims protect miRNA-3157, homologues, precursors and mimics thereof. In a second pending patent application, miRNA-3157, homologues, precursors and mimics thereof are claimed as a therapy against melanoma. A mimic of miRNA-3157 is entering preclinical development and represents InteRNA's lead product in its B-Raf/melanoma program.

"This issuance of the USPTO confirms our unique approach to identification and validation of miRNAs as drug targets and further development towards the clinic", said Roel Schaapveld, CEO of InteRNA Technologies. "It further subscribes our patent strategy and greatly strengthens our intellectual property position on miRNA drug candidates."

The latest data on miRNA-3157 as drug candidate for the treatment of human melanoma will be presented at the Society for Melanoma Research 2012 Congress, November 8-11 in Hollywood, CA, USA.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

InteRNA Technologies Secures Final Extension Series A Financing
Company has announced Hans Schikan as new chairman of its Supervisory Board.
Saturday, October 31, 2015
InteRNA Technologies, UCB and University of Bonn to Collaborate
Agreement on the role of microRNAs in neurodegenerative disease.
Friday, January 10, 2014
MiRacle Consortium Receives a € 1.2 Million FP7 Grant from the European Union
Therapeutic development of cancer cell-specific targeting of novel tumor-selective lethal miRNAs for the treatment of head and neck cancer – acronym: MiRacle.
Monday, November 04, 2013
InteRNA Technologies Announces Closing of Equity Financing Round
Company secures additional equity financing to progress lead program for melanoma treatment.
Friday, September 06, 2013
InteRNA Technologies Receives Notice of Allowance from USPTO
Patent covers the precursor and mature sequences of miRNA-3157, the Company's lead product in its B-Raf/melanoma program.
Tuesday, October 16, 2012
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Researchers Find a Gap in the Brain’s Firewall Against Parkinson’s Disease
Researchers at NIH have found mouse study that identified a key player in the progression of the disorder.
Fat Cells That Amplify Nerve Signals in Response to Cold Also Affect Blood Sugar Metabolism
Researchers at UTSW have found that the protein connexin 43 forms cell-to-cell communication channels on the surface of emerging beige fat cells that amplify the signals from those few nerve fibers.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
C Dots Show Powerful Tumor Killing Effect
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Faecal Bacteria Linked to Body Fat
Researchers at King’s College London have found a new link between the diversity of bacteria in human poo – known as the human faecal microbiome - and levels of abdominal body fat.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!